Momenta Pharmaceuticals, Inc. (MNTA): Momenta, Sandoz Can’t Dodge Amphastar An...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	22
Posts	3696
Boards Moderated	0
Alias Born	07/20/2006

floblu14

Re: None

Tuesday, 03/20/2018 4:24:08 PM

Tuesday, March 20, 2018 4:24:08 PM

Momenta, Sandoz Can’t Dodge Amphastar Antitrust Suit
By Chris Villani

Law360, Boston (March 20, 2018, 2:50 PM EDT) -- A Massachusetts federal judge Monday declined a bid by Momenta Pharmaceuticals Inc. and Sandoz Inc. to toss a suit by Amphastar Pharmaceuticals, ruling that the plaintiff company had made a reasonable case that it was harmed by their alleged stifling of competition for a generic anticoagulant.

In a 19-page order released Monday, U.S. District Judge Nathaniel M. Gorton denied Momenta and Sandoz's motion to dismiss, saying that allegations claiming they conspired to trick the U.S. Pharmacopeial Convention into adopting a method to test the anticoagulant enoxaparin...

To view the full article, register now.

https://www.law360.com/lifesciences/articles/1024002/momenta-sandoz-can-t-dodge-amphastar-antitrust-suit

What's next? Does MNTA forfeit the $35M Bond or do they (MNTA/SANDOZ) appeal? Or, is this a losing cause considering enoxaparin's current market worth? Comments?